• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Modified vaccinia Ankara     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatPoxviruses, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatVaccinesvaccineyago:Agent109190918yago:AnimalVirus101335659yago:Antigen115037339yago:CausalAgent100007347yago:Immunogen103562739yago:InfectiousAgent109312843yago:LivingThing100004258yago:Matter100020827yago:Microorganism101326291yago:Object100002684yago:Organism100004475yago:PhysicalEntity100001930yago:Poxvirus101333731yago:WikicatGeneticallyModifiedOrganismsdrugyago:Substance100020090yago:Vaccine104517535yago:Virus101328702yago:Whole100003553yago:WikicatPoxviruses New Facet based on Instances of this Class

Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine (called MVA-BN, brand names: Imvanex in the EU, Imvamune in Canada, and Jynneos in the US) against smallpox and monkeypox, having fewer side effects than the traditional smallpox vaccine. This third-generation smallpox vaccine has the advantage that it cannot reproduce complete virions in human cells, "the block of the MVA life cycle occurs at the step of virion assembly resulting in assembly of immature virus particles that are not released from the infected cell."